// App-Quantinova.ai

PB2233 : SYSTEMATIC LITERATURE REVIEW OF HEALTH-RELATED QUALITY OF LIFE BURDEN IN PATIENTS ACROSS THE SPECTRUM OF THALASSEMIA

Researchers

Presenter

  • Khaled M. Musallam

Principal Investigators

  • Maria Rizzo

  • Louise Lombard

Medical Centers

  • Health economics and outcomes research,Agios Pharmaceuticals,Cambridge,Verenigde Staten

  • Health economics and outcomes research,Cytel Inc.,Montreal,Canadá

  • Health economics and outcomes research,Agios Pharmaceuticals,Cambridge,Verenigde Staten

  • Thalassemia Center,Burjeel Medical City,Abu Dhabi,Emirados Árabes Unidos

  • Thalassemia Center,Burjeel Medical City,Abu Dhabi,Förenade Arabemiraten

  • Health economics and outcomes research,Agios Pharmaceuticals,Cambridge,Verenigde Staten

  • Thalassemia Center,Burjeel Medical City,Abu Dhabi,Förenade Arabemiraten

  • Health economics and outcomes research,Cytel Inc.,Montreal,Canadá

  • Health economics and outcomes research,Cytel Inc.,Montreal,Canadá

  • Thalassemia Center,Burjeel Medical City,Abu Dhabi,Förenade Arabemiraten

  • Health economics and outcomes research,Agios Pharmaceuticals,Cambridge,Verenigde Staten

  • Health economics and outcomes research,Agios Pharmaceuticals,Cambridge,Verenigde Staten

  • Health economics and outcomes research,Cytel Inc.,London,Соединённое Королевство

  • Health economics and outcomes research,Agios Pharmaceuticals,Cambridge,Verenigde Staten

  • Thalassemia Center,Burjeel Medical City,Abu Dhabi,Emirados Árabes Unidos

  • Thalassemia Center,Burjeel Medical City,Abu Dhabi,Emirados Árabes Unidos

  • Thalassemia Center,Burjeel Medical City,Abu Dhabi,Förenade Arabemiraten

  • Health economics and outcomes research,Cytel Inc.,Montreal,Canadá

  • Thalassemia Center,Burjeel Medical City,Abu Dhabi,Emirados Árabes Unidos

  • Health economics and outcomes research,Agios Pharmaceuticals,Cambridge,Verenigde Staten

  • Thalassemia Center,Burjeel Medical City,Abu Dhabi,Объединённые Арабские

Locations

  • United Arab Emirates

  • Canada

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Thalassemia

  • Non‐transfusion‐dependent β‐thalassaemia

Biomarkers

  • Tumor doubling time

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved